TransThera Sciences (Nanjing), Inc.

药捷安康(南京)科技股份有限公司

02617.HK

Clinical-stage biopharmaceutical company developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Its core product, Tinengotinib, a multi-targeted kinase inhibitor, is in registrational trials for cholangiocarcinoma in China and the US, with a pipeline of five clinical-stage candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Investments and fair-value assets
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech